A Multicenter, Randomized, Double-blind, Parallel-group, Phase 3 Study To Demonstrate Non-inferiority For The Efficacy Of A Once Daily Dose Of Tofacitinib Modified Release Tablet To A Twice Daily Dose Of The Immediate Release Tablet In Adult Patients With Rheumatoid Arthritis On Background Methotrexate
Phase of Trial: Phase III
Latest Information Update: 20 Apr 2017
At a glance
- Drugs Tofacitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Pfizer
- 07 Jun 2017 Biomarkers information updated
- 16 Apr 2017 Status changed from active, no longer recruiting to completed.
- 17 Jan 2017 Status changed from recruiting to active, no longer recruiting.